论文部分内容阅读
目的:观察美普清(盐酸丙卡特罗片)辅助治疗婴幼儿毛细支气管炎的临床疗效及安全性。方法:回顾性分析2005年10月-2011年10月收治的212例婴幼儿毛细支气管炎患者的临床资料。对照组116例给予综合治疗,治疗组96例在综合治疗基础上辅予美普清口服治疗。观察两组临床症状、体征持续时间、疗效及心率变化。结果:两组资料在年龄、性别及疾病严重程度上具有可比性,美普清应用后心率改变无明显统计学差异;治疗组临床症状、体征持续时间短于对照组(P<0.05),治疗组和对照组治愈率分别为85.4%和69.0%,差异具有统计学意义(P<0.01)。结论:美普清治疗婴幼儿毛细支气管炎可缩短病程,疗效确切,且方便、安全,可作为治疗婴幼儿毛细支气管炎的主要药物。
Objective: To observe the clinical efficacy and safety of meprobamate (Procaterol Hydrochloride Tablets) in the treatment of infantile bronchiolitis. Methods: The clinical data of 212 infants with bronchiolitis admitted from October 2005 to October 2011 were retrospectively analyzed. The control group of 116 patients given comprehensive treatment, the treatment group of 96 patients on the basis of comprehensive treatment combined with meprazole oral treatment. The clinical symptoms, signs duration, curative effect and heart rate were observed. Results: The two groups of data were comparable in age, sex and severity of disease. There was no significant difference in heart rate after application of metoprolol. The duration of clinical symptoms and signs in the treatment group was shorter than that in the control group (P <0.05) The cure rates in the group and the control group were 85.4% and 69.0%, respectively, with statistical significance (P <0.01). Conclusion: Meipuqing infant bronchiolitis can shorten the course of the disease, the curative effect is exact, convenient, safe and can be used as the main drug for the treatment of bronchiolitis in infants.